Comparative effectiveness of mitoxantrone plus prednisone versus prednisone alone in metastatic castrate-resistant prostate cancer after docetaxel failure
AK Green, RW Corty, WA Wood, M Meeneghan… - The …, 2015 - academic.oup.com
Background. Mitoxantrone was approved for use in metastatic castrate-resistant prostate
cancer (mCRPC) based on pain palliation without observed survival benefit in a small phase …
cancer (mCRPC) based on pain palliation without observed survival benefit in a small phase …
[PDF][PDF] Comparative Effectiveness of Mitoxantrone Plus Prednisone Versus Prednisone Alone in Metastatic Castrate-Resistant Prostate Cancer After Docetaxel Failure
AK GREEN, RW CORTY, WA WOOD, M MEENEGHAN… - The Oncologist, 2015 - Citeseer
Background. Mitoxantronewasapprovedforuseinmetastatic castrate-resistant prostate cancer
(mCRPC) based on pain palliation without observed survival benefit in a small phase III trial …
(mCRPC) based on pain palliation without observed survival benefit in a small phase III trial …
[HTML][HTML] Comparative Effectiveness of Mitoxantrone Plus Prednisone Versus Prednisone Alone in Metastatic Castrate-Resistant Prostate Cancer After Docetaxel …
AK Green, RW Corty, WA Wood, M Meeneghan… - The …, 2015 - ncbi.nlm.nih.gov
Background. Mitoxantronewasapprovedforuseinmetastatic castrate-resistant prostate cancer
(mCRPC) based on pain palliation without observed survival benefit in a small phase III trial …
(mCRPC) based on pain palliation without observed survival benefit in a small phase III trial …
[PDF][PDF] Comparative Effectiveness of Mitoxantrone Plus Prednisone Versus Prednisone Alone in Metastatic Castrate‐Resistant Prostate Cancer After Docetaxel Failure
AK Green, RW Corty, WA Wood, M Meeneghan… - The …, 2015 - Wiley Online Library
Background. Mitoxantrone was approved for use in metastatic castrate‐resistant prostate
cancer (mCRPC) based on pain palliation without observed survival benefit in a small phase …
cancer (mCRPC) based on pain palliation without observed survival benefit in a small phase …
Comparative Effectiveness of Mitoxantrone Plus Prednisone Versus Prednisone Alone in Metastatic Castrate-Resistant Prostate Cancer After Docetaxel Failure.
AK Green, RW Corty, WA Wood, M Meeneghan… - …, 2015 - search.ebscohost.com
Background. Mitoxantrone was approved for use inmetastatic castrate-resistant prostate
cancer (mCRPC) based on pain palliation without observed survival benefit in a small phase …
cancer (mCRPC) based on pain palliation without observed survival benefit in a small phase …
Comparative Effectiveness of Mitoxantrone Plus Prednisone Versus Prednisone Alone in Metastatic Castrate-Resistant Prostate Cancer After Docetaxel Failure
AK Green, RW Corty, WA Wood, M Meeneghan… - The …, 2015 - cdr.lib.unc.edu
Mitoxantrone was approved for use in metastatic castrate-resistant prostate cancer
(mCRPC) based on pain palliation without observed survival benefit in a small phase III trial …
(mCRPC) based on pain palliation without observed survival benefit in a small phase III trial …
Comparative effectiveness of mitoxantrone plus prednisone versus prednisone alone in metastatic castrate-resistant prostate cancer after docetaxel failure
AK Green, RW Corty, WA Wood… - The …, 2015 - pubmed.ncbi.nlm.nih.gov
Background Mitoxantrone was approved for use in metastatic castrate-resistant prostate
cancer (mCRPC) based on pain palliation without observed survival benefit in a small phase …
cancer (mCRPC) based on pain palliation without observed survival benefit in a small phase …
Comparative effectiveness of mitoxantrone plus prednisone versus prednisone alone in metastatic castrate-resistant prostate cancer after docetaxel failure.
AK Green, RW Corty, WA Wood, M Meeneghan… - The …, 2015 - europepmc.org
Background Mitoxantrone was approved for use in metastatic castrate-resistant prostate
cancer (mCRPC) based on pain palliation without observed survival benefit in a small phase …
cancer (mCRPC) based on pain palliation without observed survival benefit in a small phase …
[PDF][PDF] Comparative Effectiveness of Mitoxantrone Plus Prednisone Versus Prednisone Alone in Metastatic Castrate-Resistant Prostate Cancer After Docetaxel Failure
AK GREEN, RW CORTY, WA WOOD… - The …, 2015 - scholar.archive.org
Background. Mitoxantronewasapprovedforuseinmetastatic castrate-resistant prostate cancer
(mCRPC) based on pain palliation without observed survival benefit in a small phase III trial …
(mCRPC) based on pain palliation without observed survival benefit in a small phase III trial …